Effect of Combined Inhibition of P110 Alpha PI3K Isoform and STAT3 Pathway in Ovarian Cancer Platinum-Based Resistance

Oncotarget - United States
doi 10.18632/oncotarget.25513
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Exosomes as Mediators of Platinum Resistance in Ovarian Cancer

Oncotarget
Oncology
2017English

Antitumor Effect of Combined NAMPT and CD73 Inhibition in an Ovarian Cancer Model

Oncotarget
Oncology
2015English

mTORC1 Inhibition Is Required for Sensitivity to PI3K P110 Inhibitors in PIK3CA-Mutant Breast Cancer

Science Translational Medicine
Medicine
2013English

Approaching Resistance to Targeted Inhibition of PI3K in Breast Cancer

2011English

B7-H3 Induces Ovarian Cancer Drugs Resistance Through an PI3K/AKT/BCL-2 Signaling Pathway

Cancer Management and Research
Oncology
2019English

Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer

Cancer Discovery
Oncology
2016English

Indirubin Suppresses Ovarian Cancer Cell Viabilities Through the STAT3 Signaling Pathway

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2018English

Vertical Inhibition of the PI3K/Akt/mTOR Pathway Is Synergistic in Breast Cancer

Oncogenesis
Cancer ResearchMolecular Biology
2017English

Honokiol-Mediated Inhibition of PI3K/mTOR Pathway

Journal of immunotherapy (Hagerstown, Md. : 1997)
Cancer ResearchAllergyImmunologyPharmacology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy